SpringWorks (SWTX) an exciting $4B Biotech looking to work out of a nice triangle pattern and large volume zone with a move above $87 key. SWTX has four key catalysts in 2021: These catalysts include: i) Phase 1b/2 proof-of-concept data for the ongoing combination study of mirdametinib + BGNE’s lifirafenib in RAS/RAFm solid tumors, ii) Phase 1 results from the dose escalation portion of the study of BGB-3245 in BRAF-nonV600Em tumors, iii) initial DREAMM-5 data from a study of nirogacestat + GSK’s Blenrep (2H21), and iv) topline data from the DeFi Phase 3 study of nirogacestat in desmoid tumors (2H21). Nirogacestat for the treatment of adult desmoid tumors and mirdametinib for the treatment of NF1-associated plexiform neurofibromas could potentially reach the market in the U.S. in 2022 and 2023, respectively, marking a crucial turning point in SpringWorks’ evolution as a company.